Yang Patrick Y
Yang Patrick Y's purchase track record
Yang Patrick Y has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/21/2022 | SANA | $204K | -16.3% | -4.4% | -12.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Transaction History
| SANA | ▼ Sell | Open Market | 25,000 | $236K | 3/8/2024 | View on chart |
| CDXS | ▲ Buy | Grant | 11,273 | $0 | 6/14/2022 | View on chart |
| SANA | ▲ Buy | Open Market | 28,000 | $204K | 3/21/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 8,000 | $134K | 3/15/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 7,800 | $246K | 12/13/2021 | View on chart |
| CDXS | ▼ Sell | Open Market | 200 | $6K | 12/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Sana Biotechnology Featured in Diabetes Treatment Analysis
Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.
Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.